Wegovy pill approved in Europe – what it could mean for patients in Portugal

Weight-loss treatment in Europe is set to become significantly more convenient after the European Commission approved the first oral GLP-1 medication for obesity. Novo Nordisk’s once-daily Wegovy tablet becomes the first pill of its kind authorised across the European Union for weight management, marking a major milestone in the treatment of obesity.

Until now, Wegovy has been available as a weekly injection, while many patients have become familiar with injectable alternatives such as Ozempic, which contains the same active ingredient (semaglutide) but is licensed primarily for type 2 diabetes, and Mounjaro (tirzepatide), another weekly injection that has rapidly gained popularity for weight loss.

For many people, the prospect of taking a daily tablet instead of giving themselves a weekly injection could remove one of the biggest barriers to treatment. Healthcare professionals believe an oral option may encourage more eligible patients to seek medical help, particularly those who have been reluctant to use injectable medicines.

The new tablet is intended for adults with obesity, or those who are overweight and have at least one weight-related health condition, such as hypertension or type 2 diabetes. As with the injectable version, it is designed to be used alongside a reduced-calorie diet and increased physical activity rather than as a standalone solution.

For patients in Portugal, however, EU approval does not necessarily mean the medicine will appear immediately in pharmacies. Novo Nordisk must still determine its commercial launch timetable for individual countries, while pricing and reimbursement discussions will need to take place with the Portuguese medicines regulator, Infarmed. Initially, the medicine is also likely to be available mainly through private prescription, as has been the case with many of the newer GLP-1 weight-loss treatments.

The approval is also likely to intensify competition in what has become one of the fastest-growing sectors of the pharmaceutical industry. Eli Lilly, the manufacturer of Mounjaro, is already developing oral versions of its own obesity medicines and has made significant progress with tablet-based GLP-1 therapies. Industry analysts expect several competing oral treatments to reach European markets over the next few years, potentially increasing patient choice and placing downward pressure on prices as competition grows.

As for Ozempic, it is worth noting that an oral form of semaglutide already exists under the brand name Rybelsus, but it is approved for the treatment of type 2 diabetes rather than obesity. The newly approved Wegovy tablet is specifically licensed for weight management and represents the first oral GLP-1 treatment in Europe with that indication.

With obesity affecting a growing proportion of Portugal’s adult population, the arrival of an effective tablet could make treatment accessible to many more people. However, experts continue to stress that these medicines are intended for patients who meet clinical criteria and should always be prescribed and monitored by healthcare professionals, rather than being viewed as a quick fix for cosmetic weight loss.

Portugal Resident

The Latest News from Portugal in english. Explore Portugal News, Algarve News, Portugal Events, Community, Business, Lifestyle from Portugal Resident.